Bezlotoxumab (Zinplava)

Covered: a single IV dose of bezlotoxumab (Zinplava) up to 10 mg/kg to reduce recurrence of Clostridium difficile infection when given with antibacterial therapy; off‑label uses and repeat dosing are excluded. Key requirements: documented CDI diagnosis, concurrent antibacterial treatment for CDI, high risk for recurrence, no prior receipt of bezlotoxumab, and approval limited to one 10 mg/kg IV dose.

"To reduce the recurrence of Clostridium difficile infection (CDI) in individuals who are receiving antibacterial drug treatment for CDI and are at a high risk for CDI recurrence."

Sign up to see full coverage criteria, indications, and limitations.